Lexaria Bioscience Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Lexaria Bioscience Corp. on June 20, 2018, covering events that occurred on June 19, 2018. The filing reports on unregistered sales of equity securities and related Regulation FD disclosures.
Key Financial Metrics
The filing details the receipt of capital through the exercise of previously granted warrants and stock options. No commissions or placement fees were paid in connection with these transactions. Proceeds are designated for general corporate purposes.
| Instrument Type | Quantity Exercised | Exercise Price (USD) | Total Proceeds (USD) | Recipient Category |
|---|---|---|---|---|
| Warrants | 50,000 | $0.60 | $30,000 | Third Parties (Non-officers/Directors) |
| Warrants | 450,000 | $0.14 | $63,000 | Company Officer |
| Stock Options | 247,500 | $0.091 | $22,500 | Company Officer |
| Total | 747,500 | - | $115,500 | - |
Note: The press release referenced in Item 7.01 cites total proceeds of $115,250, while the sum of the specific line items in Item 3.02 equals $115,500. The filing text does not provide a clear explanation for this $250 discrepancy.
Material Changes
This report does not provide comparative financial data (revenue, profit, cash flow, or margins) against prior periods. The material change reported is the increase in cash assets and outstanding share count resulting from the specific warrant and option exercises detailed above.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure that the securities were not registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption.
Investor Verification Checklist
- Verify the exact total proceeds received ($115,250 vs. $115,500) by reviewing the attached press release (Exhibit 99.1).
- Confirm the updated total number of outstanding shares following the issuance of 747,500 new shares.
- Review the company's most recent 10-K or 10-Q for baseline liquidity and debt positions, as this 8-K does not provide a full balance sheet.
- Check for any subsequent filings regarding the use of proceeds for general corporate purposes.